Evidence map›Paper›PMID 30968244›Full record

ArticleClinical and experimental nephrology2019

Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study.

Satoshi Iimuro, Tetsuji Kaneko, Yasuo Ohashi, Tsuyoshi Watanabe, Kosaku Nitta, Tadao Akizawa, Seiichi Matsuo, Enyu Imai, Hirofumi Makino, Akira Hishida and 1 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Preventable Hospitalizations and Kidney Care.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  3. Article
  4. Article
  5. Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  6. Article
  7. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Satoshi IimuroTeikyo Academic Research Center, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, Japan. siitky@gmail.com.ORCID http://orcid.org/0000-0001-7777-4555
Tetsuji KanekoTeikyo Academic Research Center, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, Japan.
Yasuo OhashiDepartment of Integrated Science and Engineering for Sustainable Society, Chuo University, Bunkyo-ku, Tokyo, Japan.
Tsuyoshi WatanabeJapan Organization of Occupational Health and Safety Fukushima Rosai Hospital, Iwaki-city, Fukushima, Japan.
Kosaku NittaDepartment of Nephrology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Tadao AkizawaDivision of Nephrology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.
Seiichi MatsuoDepartment of Nephrology, Nagoya University, Nagoya, Aichi, Japan.
Enyu ImaiNakayamadera Imai Clinic, Takarazuka, Hyogo, Japan.
Hirofumi MakinoOkayama University, Okayama, Okayama, Japan.
Akira HishidaYaizu City Hospital, Yaizu, Shizuoka, Japan.
CKD-JAC Investigators
Teikyo University · JPJapan Organization of Occupational Health and Safety · JPOkayama University · JPShowa University · JPShizuoka University of Welfare · JPTakara (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease is a known risk factor for end-stage renal and cardiovascular diseases. However, data are limited on the causes of hospitalization in patients with chronic kidney disease of maintenance period. This study aimed to aggregate hospitalization data of CKD patients and to determine the high-risk population. In addition, we compared CKD population to general population.

methodsWe conducted a post hoc analysis of the chronic kidney disease-Japan cohort study, a multicenter prospective cohort study of 2966 patients with chronic kidney disease with a median 3.9 years of follow-up. We examined the hospitalization reasons and analyzed the risk factors.

resultsWe found 2897 all-cause hospitalization events (252.3 events/1000 person-years), a hospitalization incidence 17.1-fold higher than that in an age- and sex-matched cohort from the general Japanese population. Kidney, eye and adnexa, and heart-related hospital admissions were the most common. All-cause hospitalization increased with chronic kidney disease stage and with the presence of diabetes. Patients with diabetes at enrollment had 345.7 hospitalization events/1000 person-years, which is considerably higher than 196.8 events/1000 person-years for those without diabetes. Survival analysis, using hospitalization as an event, showed earlier all-cause hospitalization with the progression of chronic kidney disease stage and diabetes. Cardiovascular disease hospitalizations were more strongly influenced by diabetes than chronic kidney disease stage.

conclusionsPatients with chronic kidney disease and diabetes are highly vulnerable to hospitalization for a variety of diseases. These descriptive data can be valuable in predicting the prognosis of patients with chronic kidney disease.

Indexed as

Patient AdmissionAgedDiabetes MellitusDisease ProgressionFemaleHumansJapanMaleMiddle AgedPrognosisProspective StudiesRenal Insufficiency, ChronicRisk AssessmentRisk FactorsTime FactorsCardiovascular diseaseDiabetes mellitusDiabetic kidney diseaseJapanese patient survey 2008Pre-renal replacement therapy

Identifiers

PMID30968244
PMCPMC6555784
OpenAlexW2937355502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.